Mobile

A study to evaluate the safety and effect of the 2 experimental drugs ABT-493/ABT-530 in people with HCV. "Experimental" means that they have not been approved by any regulatory agency for sale to th...

Update Il y a 4 ans
Reference: EUCTR2015-002348-14

A study to evaluate the safety and effect of the 2 experimental drugs ABT-493/ABT-530 in people with HCV. "Experimental" means that they have not been approved by any regulatory agency for sale to the public

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objectives of this study are to assess the efficacy (SVR12) HCV RNA < lower limit of quantification (LLOQ) 12 weeks following 12 weeks of treatment of the ABT-493/ABT-530 combination regimen and the safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen compared to placebo, in adults with chronic HCV genotype (GT) 2 infection without underlying cirrhosis.

Inclusion criteria

  • Chronic HCV Infection

Links